InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - ETF Exposure

Current share price for TLX : $13.210 0.12 (0.90%)+

Telix Pharmaceuticals Limited (TLX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a global biopharmaceutical company engaged in the development and commercialization of targeted therapeutic and diagnostic radiopharmaceuticals, along with supporting medical technologies. Headquartered in Melbourne, Australia, Telix maintains strategic international operations across the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan.

TLX General Information +

ASX Code TLX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 4,495
TLX Share Price $13.210
Day High $13.490
Day Low $13.140
Last Close $13.330
TLX Share Price Movement $0.12 ( 0.90% )
Prices as at 16:40, 18 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to TLX

As a significant Australian company by market capitalisation, TLX is held across 25 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when TLX moves, funds like IMPQ, M1DS, MVE, FAIR and VSO that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 2.8% to TLX , while the average exposure across all 25 ETFs that hold it is around 0.5% .

Top ETF holdings

Last updated: ETF data and holdings as at 17 November 2026

Own TLX directly or through an ETF?

How does holding Telix Pharmaceuticals Limited (TLX) shares directly compare to ETFs that include it?

TLX Direct
IMPQ
ASX
M1DS
CBOE
MVE
ASX
FAIR
ASX
VSO
ASX
Holdings 1 company 42 holdings 62 holdings 53 holdings 95 holdings 204 holdings
TLX Weight 100% 2.8% 2.2% 1.2% 0.9% 0.7%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only - - 0.45% p.a. 0.49% p.a. 0.3% p.a.
Approx. Yield - - - 2.63% 2.97% 4.97%
Star Ratings - Not Rated star starstarstarstar starstarstarstar starstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not TLX's direct yield. Annual cost uses each ETF's MER.

TLX Exposure on $10,000 investment

How a $10,000 investment in Telix Pharmaceuticals Limited (TLX) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Telix Pharmaceuticals Limited (TLX) Direct share $13.210 -4.28% -$428 $9,572
eInvest Better Future (Managed Fund) (IMPQ) - $3.980 0% $0 $10,000
Paradice Australian Mid Cap Fund Active ETF (M1DS) Equity - Australia Strategy $6.250 0.48% +$48 $10,048
VanEck S&P/ASX MidCap ETF (MVE) Equity - Australia Small/Mid Cap $44.190 -3.81% -$381 $9,619
BetaShares Australian Sustainability Leaders ETF (FAIR) Equity - Australia Strategy $19.480 -0.81% -$81 $9,919
Vanguard MSCI Australian Small Companies Index ETF (VSO) Equity - Australia Small/Mid Cap $70.290 -4.73% -$473 $9,527

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Telix Pharmaceuticals Limited (TLX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Telix Pharmaceuticals Limited (TLX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Telix Pharmaceuticals Limited (TLX) price-sensitive announcements

TLX - Telix Reports Third Quarter 2026 Financial Performance
Telix Pharmaceuticals Limited reported Q3 2026 unaudited financial performance for the qua
Telix Pharmaceuticals Limited (TLX)
21 Oct 2026 | 8:36 AM
TLX - FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
Telix Pharmaceuticals Limited announced that the U.S. FDA granted Fast Track designation t
Telix Pharmaceuticals Limited (TLX)
30 Sep 2026 | 8:20 AM
TLX - Telix and ITM Join Forces to Create Radiopharma Powerhouse
The presentation dated 21 September 2026 outlines Telix Pharmaceuticals Limited’s proposed
Telix Pharmaceuticals Limited (TLX)
21 Sep 2026 | 8:38 AM
TLX - Telix and ITM Join Forces to Create Radiopharma Powerhouse
Telix Pharmaceuticals Limited announced on 21 September 2026 that it had signed a strategi
Telix Pharmaceuticals Limited (TLX)
21 Sep 2026 | 8:37 AM

Telix Pharmaceuticals Limited (TLX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Appendix 3Y Maria Rivas 5 Nov 2026 8:22AM $13.320 $13.210 fallen by 0.83%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Telix Capital Markets Day Presentation November 2026 4 Nov 2026 8:23AM $13.000 $13.210 risen by 1.62%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Change of Director's Interest Notice - Marie McDonald 3 Nov 2026 7:04PM n/a $13.210 n/a
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Notification regarding unquoted securities - TLX 3 Nov 2026 6:33PM $13.000 $13.210 risen by 1.62%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Cancellation of Appendix 2A 3 Nov 2026 8:40AM $13.080 $13.210 risen by 0.99%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
Health Care $4,496 Telix Notice of General Meeting, Proxy Form and Online Guide 30 Oct 2026 8:15AM $13.480 $13.210 fallen by 2%

TLX Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025F $122.66 $34.57 61.00% 82.53 0.00 0.00% 0.0%
2024F $76.18 $21.47 5.70% 132.88 0.00 0.00% 0.0%
2023A $65.73 $20.31 -174.80% 46.74 0.00 0.00% 0.0%

TLX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 F 2025 F 2023 A 2024 F 2025 F 2023 A 2024 F 2025 F
CSL Limited (CSL) $97,186M 0.7309 -0.4374 0.0602 12.5465 22.3000 21.0343 2.10% 2.11% 2.18%
Clinuvel Pharmaceuticals Limited (CUV) $383M -0.0696 -0.0719 0.0242 11.3623 12.2419 11.9528 0.66% 0.66% 0.66%
Mesoblast Limited (MSB) $2,453M -0.4501 0.0000 0.0000 0.0000 0.0000 856.8182 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,763M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,557M -1.3893 0.0000 -0.5229 0.0000 156.9754 328.9926 0.00% 0.00% 0.00%

TLX Directors

Name Position Start Date
Dr Christian Peter Behrenbruch Chief Executive Officer, Managing Director 3 Jan 2017
Ms Jann E Skinner Non-Executive Director 19 Jun 2018
Ms Marie Elizabeth McDonald Non-Executive Director 3 Mar 2025
Dr Mark Alexander Nelson Non-Executive Director 17 Sep 2017
Dr Maria Rivas Non-Executive Director 11 May 2026
Mr William (Bill) Jellison Non-Executive Director 11 May 2026
Mr David Gill Non-Executive Director, Non-Executive Chairman 11 May 2026

Telix Pharmaceuticals Limited (TLX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
30 Oct 2026 RIVAS, Maria Buy Direct Shares 9,000 $9.034 $81,306.000
27 Oct 2026 MCDONALD, Marie Buy Indirect Shares 7,812 $12.808 $100,059.221
26 Oct 2026 BEHRENBRUCH, Christian Buy Indirect Shares 38,750 $12.894 $499,623.125

See all changes in directors' interest & trades for Telix Pharmaceuticals Limited (TLX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TLX Management

Name Position
Raphael Ortiz Chief Executive Officer, Telix International
Kevin Richardson Chief Executive Officer, Telix Precision Medicine
Richard Valeix Chief Executive Officer, Telix Therapeutics
Marcin Firek Company Secretary
Darren Smith Group Chief Financial Officer
David Cade Group Chief Medical Officer
Mary Jessel Group Chief of Clinical Affairs
Darren Patti Group Chief Operating Officer
Lena Moran-Adams Group General Counsel
Meredith Crowe Senior Vice President, People & Culture

TLX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (TLX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
28,187,775 (8.30%) State Street Corporation and subsidiaries
22,419,015 (6.60%) JPmorgan Chase & Co. and its affiliates
20,675,000 (6.10%) Elk River Holdings Pty Ltd
20,675,000 (6.10%) Gnosis Verwaltungsgesellschaft

TLX Calendar of Events

Date Event
19 August 2027 Report (Interim)
19 February 2027 Report (Annual)
19 February 2027 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.